Could the Mediterranean diet protect the brain through the gut?

By Dr. Liji Thomas, MDReviewed by Lauren HardakerSep 27 2026

From microbial metabolites to inflammation and the blood-brain barrier, researchers trace how Mediterranean eating could influence neurodegeneration, while exposing a crucial gap in the evidence.

Review: Gut Microbiome-Mediated Neuroprotective Effect of the Mediterranean Diet: A Narrative Review of Cognitive Aging, Alzheimer’s Disease, and Parkinson’s Disease. Image Credit: LipeBorges_Foto / Shutterstock

A recent narrative review published in the journal Nutrients found that direct human evidence showing that Mediterranean diet (MD)-induced microbiome changes mediate its potential neuroprotective effects remains limited.

Background

Neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) comprise a growing disease segment that imposes a substantial burden on the patient as well as on societal, economic, and public health resources.

With no curative therapies in sight, there is a need for strategies to preserve brain health and prevent or delay the onset and progression of disease.

The MD is among the most promising lifestyle modifications for reducing the risk of cognitive decline. It is characterized by high intakes of fruits, vegetables, whole grains, legumes, nuts, and seeds, with extra-virgin olive oil (EVOO), fish, poultry, and fermented dairy products in moderation.

This provides high levels of bioactive compounds, including omega-3 fatty acids, vitamins, and minerals, that mitigate oxidative stress, regulate inflammation, improve vascular function, and reduce neuroinflammation and neuronal injury.

MD adherence is linked to slower cognitive decline and a reduced risk of dementia, AD in particular. Yet the role of the gut microbiome in these effects remains unclear.

The gut microbiome comprises trillions of gut microbes that are important for intestinal, immune, and neurological homeostasis. They communicate with the central nervous system through the gut-brain axis, signaling through microbial metabolites, immune mediators, hormones, and vagal nerve impulses.

Dysbiosis, or disruption of the gut microbiome, involves altered microbial composition, reduced diversity, and impaired microbial function, which may compromise the intestinal epithelial barrier. It may lead to increased intestinal permeability, allowing the translocation of microbes and pro-inflammatory microbial components, such as lipopolysaccharides (LPS), into the systemic circulation, thereby promoting chronic low-grade inflammation.

Systemic inflammation may subsequently increase blood-brain barrier permeability, oxidative stress, and microglial activation within the central nervous system, processes implicated in neurodegeneration.

In view of the limited direct evidence that MD-induced microbiome changes mediate the associated neuroprotection, the current narrative review sought to evaluate their role.

MD components and microbial metabolites

The MD may promote microbial diversity and metabolic resilience within the gut microbiome. It provides diverse metabolic substrates for colonic microbes, including fiber and other nondigestible carbohydrates from whole grains, legumes, fruits and vegetables, nuts, and seeds.

Their fermentation may generate short-chain fatty acids (SCFAs), such as butyrate, which promote epithelial function and mucus production, and support intestinal barrier integrity. By limiting translocation and through their immunomodulatory effects, SCFAs may reduce local and systemic inflammation, oxidative stress, and metabolic dysfunction.

Yet SCFAs are not universally beneficial; their effects depend on the specific metabolite and host environment.

Other MD-associated microbial metabolites include secondary bile acids, which have metabolic and immunoregulatory properties, and indoles, which regulate mucosal immunity and inflammatory signaling and support epithelial integrity.

EVOO provides monounsaturated fatty acids (MUFAs), predominantly oleic acid, and phenolics that may have prebiotic effects, potentially promoting the growth of SCFA-producing bacteria in the microbiome. This may increase SCFA production and influence intestinal epithelial function and inflammation.

Fatty fish provide the long-chain omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), while some nuts, particularly walnuts, provide the plant-derived omega-3 alpha-linolenic acid. Omega-3 fatty acids may reduce oxidative stress and inflammatory signaling, regulate immune responses, and alter the microbiome and metabolite profile, though these effects vary according to diet, microbiome composition, dose, and metabolic status.

Fermented dairy products like yogurt and kefir yield live microbes and fermentation compounds that influence the microbiome and metabolic pathways, and intestinal immune signaling. Yet probiotic benefits are product- and strain-specific.

Mechanisms of microbiome-related neuroprotection

MD components and microbial metabolites build antioxidant capacity, exert anti-inflammatory activity, and support intestinal barrier integrity.

Microbial metabolites, especially SCFAs, may also support regulatory T cell (Treg) function. Tregs help maintain immune tolerance towards dietary antigens and commensals. These effects may help limit excessive and sustained inflammation, reducing circulating inflammatory cytokines. This in turn may attenuate neuroinflammatory signaling.

Trimethylamine N-oxide (TMAO) is produced through microbial and host metabolism of dietary choline, betaine, and carnitine. High levels have been linked in some studies to metabolic and vascular dysfunction, and to inflammation and oxidative stress, all of which are implicated in neurodegeneration.

The authors caution, though, that dietary composition may influence TMAO production and potentially affect brain health, while TMAO does not have uniformly harmful effects.

Taken together, these findings suggest that MD-associated microbial metabolites may influence host immune-inflammatory physiology, presenting a plausible mechanism of neuroprotection.

Intestinal barrier function

Intestinal epithelial barrier function is key to intestinal homeostasis and immune tolerance. Both MD components and associated microbial metabolism promote colonocyte health, epithelial function, and mucus production, protecting intestinal barrier integrity. In parallel, their anti-inflammatory and antioxidant activity may support blood-brain barrier integrity by attenuating systemic inflammation.

In turn, this may limit chronic microglial activation, reduce neuroinflammation, and preserve neuronal resilience and synaptic function. The authors describe microglial regulation as a potential convergence point for multiple neuroprotective mechanisms mediated by the MD-associated microbiome remodeling.

Mitochondrial function

Sustained oxidative stress is a major contributor to neurodegeneration, as neurons are particularly sensitive to damage from reactive oxygen species (ROS). Mitochondria are key to providing ATP for neurons' energy needs but are also major sources and targets of ROS, linking mitochondrial dysfunction closely to oxidative stress.

Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of both AD and PD. MD components such as polyphenols, unsaturated fats, and other bioactive compounds, along with SCFAs produced by MD-associated microbes, may together increase antioxidant capacity, reduce systemic inflammation, and limit mitochondrial damage, potentially reducing the risk of neuronal injury.

Possible MD mechanisms common to AD and PD prevention

Multiple interconnected pathways influence the risk of both AD and PD. Amyloid-β (Aβ) peptides aggregate to form oligomers, fibrils, and plaques characteristic of AD. This process is affected by factors such as APOE, α-synuclein, and β2-microglobulin (β2M).

α-synuclein aggregation is key to PD pathogenesis as it induces mitochondrial dysfunction and inflammation. Such aggregation has been documented in gut nervous tissue and colonic biopsies from people with prodromal PD, supporting the hypothesis that PD-related disease changes may begin in the gut and spread via the vagus nerve to the brain.

While elevated B2M is linked to increased Aβ aggregation in AD, it is associated with inhibition of α-synuclein aggregation in PD.

Many of these processes may be influenced by MD-associated dietary components and microbial metabolites, such as increased SCFA production and reduced inflammatory signaling. AD patients have lower mean abundance of SCFA-producing taxa and higher abundances of pro-inflammatory bacteria. These changes are associated with increased amyloid plaque and tau pathology, as well as cognitive decline.

The authors suggest that these associations might indicate a potential upstream effect of the MD on neurodegenerative processes.

The presence of the APOE ε4 gene variant is an established genetic risk factor for late-onset AD and has also been associated with PD susceptibility, age at onset, cognitive decline, and Parkinson's disease dementia. This allele is associated with central and peripheral inflammatory and immune activation. MD-associated microbiome changes are associated with potentially beneficial regulation of systemic and intestinal inflammatory signaling. The interaction between MD and APOE ε4 carriage might underlie interindividual variation in outcomes among MD-adherent groups and warrants further investigation.

Relevance to health outcomes

Human studies have linked greater MD adherence with favorable microbiome changes, a lower risk of major cardiometabolic events, and better neurological outcomes. Yet there is little direct evidence that MD-induced microbiome remodeling mediates long-term reductions in AD and PD risk.

Mechanistic evidence is also less developed for PD than for AD, with most human studies examining disease risk or prodromal features rather than showing how MD-induced microbiome changes influence PD pathology.

Differences in study design and methodology may strongly influence the types of dietary exposures and microbiome alterations observed. This heterogeneity makes it difficult to evaluate the role of microbiome change in MD-associated neuroprotection.

Reverse causality is another concern that prospective studies must address. MD adherence is also often part of a broader health-promoting lifestyle. Socioeconomic factors may also confound observed MD-associated reductions in neurodegeneration risk.

Together, these limitations explain the lack of an established causal pathway between diet, the microbiome, and the brain in MD.

Conclusions

This review synthesized fragmented evidence linking MD adherence to microbiome function, immune regulation, intestinal barrier function, and neurodegeneration-linked changes in the brain. The evidence supports biologically plausible links among these processes, but the findings do not establish the directionality of these associations or demonstrate that MD-associated microbiome remodeling mediates the diet's neurological benefits.

Long-term randomized controlled trials or well-designed longitudinal intervention studies would be necessary to clarify these relationships. The use of artificial intelligence (AI) in wearable health technologies may make it easier to capture dietary patterns with lower participant burden, while integrating other physiological markers with dietary and microbiome-related markers. This approach may advance precision nutrition in this area.